Our new series of implementation briefs focuses on tactical issues stakeholders may face in adopting and paying for innovative cell and gene therapies.

Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with a focus on addressing these challenges for the new sickle cell disease (SCD) therapies, Casgevy and Lyfgenia. ​